Screening for hepatocellular carcinoma;Screening dell'epatocarcinoma

Minerva Medica

Volumn 96, Issue 2, 2005, Pages 95-108

  Leone, N ^a   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Alpha fetoprotein; Des carboxy prothrombin; Hepatocellular carcinoma; Liver cirrhosis,; Screening; Ultrasonography

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN;

CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MEDICAL LITERATURE; OVERALL SURVIVAL; REVIEW; SEROLOGY;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; PROTEIN PRECURSORS; PROTHROMBIN; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745387491     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Parking DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J. Cancer incidence in five continents. Lyon IARC Scientific Publications: World Health Organization. Geneva: WHO; 1995. p. 117-29.
2. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998;29:944-52.
3. Horiike N, Fujisawa T, Michitaka K, Tada K, Masumoto T, Iuchi H et al. The effectiveness of Interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep 1998;5:1171-4.
4. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997;25:259-62.
5. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106:1000-5.
6. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990;150:1051-4.
7. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
8. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
9. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990;12:753-60.
10. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.
11. Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio Tommasini M, Donato MF et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80.
12. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994;74:2234-8.
13. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
14. Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994;74:2442-8.
15. Cottone M, Turn M, Caltagirone M, Parisi P, Orlando A, Fiorentino G et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994;21:1029-34.
16. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977-85.
17. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.
18. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995;108:812-7.
19. Levrero M, Balsano C, Avantaggiati ML, Natoli G, De Marzio E, Will H. Hepatitis B virus and hepatocellular carcinoma: a possible role for the viral transactivators. Ital J Gastroenterol 1991;23:576-83.
20. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-6.
21. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-8.
22. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990;335:873-4.
23. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
24. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L et al. Hepatitis C virus infetion as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992;116:97-102.
25. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
26. Resnick RH, Stone K, Antonioli D. Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis. Dig Dis Sci 1983;28:908-11.
27. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003;23:405-9.
28. Bassendine MF. Alcohol a major risk factor for hepatocellular carcinoma. J Hepatol 1986;2:513-9.
29. Takada A, Nei J, Takase S, Matsuda Y. Effects of ethanol on experimental hepatocarcinogenesis. Hepatology 1986;6:65-72.
30. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong expereince. Hepatology 2000;31:330-5.
31. Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000;6:320-5.
32. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44.
33. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatoellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
34. Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996;91:1189-94.
35. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh Class A cirhhosis. Am J Med 1996;101:422-34.
36. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-years population-based study. Hepatology 2000;32:842-6.
37. Izzo F, Cremona F, Ruffolo F, Palaia R, Parisi V, Curley S. Detection of hepatocellular cancer during screening of 1125 patients with chronic hepatitis virus infection. J Chemother 1997;9:151-2.
38. Giannini E, Arzani L, Borro P, Botta F, Fasoli A, Risso D et al. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology 2000;47:1395-8.
39. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986;90:263-7.
40. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12:680-7.
41. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20:65-71.
42. Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52:iii1-8.
43. Iavarone M, Lampertico P, Ronchi G, Del Ninno E, Zanella A, Colombo M. A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis. J Viral Hepat 2003;10:423-6.
44. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000;95:1036-40.
45. Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S et al. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa-fetoprotein. Ann Surg Oncol 1999;6:178-85.
46. Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997;109:458-63.
47. Larcos G, Sorokopud H, Berry G, Farrell GC. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. Am J Roentgenol 1998;171:433-5.
48. Nagai T, Murota M, Nishioka M, Fujita J, Ohtsuki Y, Dohmoto K et al. Elevation of cytokeratin 19 fragment in serum in patients with hepatoma: its clinical significance. Eur J Gastroenterol Hepatol 2001;13:157-61.
49. Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996;91:1380-3.
50. Raedle J, Roth WK, Oremek G, Caspary WF, Zeuzem S. Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sci 1995;40:2587-94.
51. Sassa T, Kumada T, Nakano S, Uematsu T. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999;11:1387-92.
52. Tsuzurahara S, Sata M, Iwamoto O, Shichijo S, Kojiro M, Tanikawa K et al. Detection of MAGE-4 protein in the sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis. Jpn J Cancer Res 1997;88:915-8.
53. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-γ-carboxyprothrombin in the early stages of hepatocellular carcinoma. Hepatology 1990;11:481-7.
54. Tsai JF, Jeng JE, Chuang LY, Chang WY, Tsai JH. Urinary transforming growth factor beta levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease. Hepatology 1997;25:1141-6.
55. Izzo F, Cremona F, Ruffolo F, Palaia R, Parisi V, Curley SA. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Ann Surg 1998;227:513-8.
56. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
57. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001;16:553-9.
58. Van Roey G, Fevery J, Van Steenbergen W. Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol 2000;12:61-6.
59. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002;35:S86-S91.
60. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS et al. Screening test for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review. Hepatology 2002;36:S84-92.
61. Gupta S, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS et al. Test characteristics of alfa-fetoprotein for detection hepatocellular carcinoma in patients with hepatitis C. Ann Intern Med 2003;139:46-50.
62. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
63. Bolondi L, Benzi G, Santi V, Gaiani S, Li Bassi SL, Zironi G et al. Relationship between alpha-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population. Ital J Gastroenterol 1990;22:190-4.
64. Sato Y, Nakato K, Kato Y, Shima M, Ishii N, Koji T et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. New Engl J Med 1993;328:1802-6.
65. Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988;61:769-74.
66. Liebman HA, Furie BC, Tong M, Blanchard RA, Lo KJ, Lee SD et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
67. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T. Clinical usefulness of gamma-carboxyprothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 1991;12:1787-92.
68. Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H et al. Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170-6.
69. Sakon M, Monden M, Gotoh M, Kobayashi K, Kanai T, Umeshita K et al. The effects of Vitamin K on the generation of des-γ-carboxyprothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Am J Gastroenterol 1991;86:339-45.
70. Nakao A, Suzuki Y, Isshiki K, Kimura Y, Takeda S, Kishimoto W et al. Clinical evaluation of plasma abnormal prothrombin (des-γ- carboxyprothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol 1991;86:62-6.
71. Tsuchida S, Hoshino K, Sato T, Ito N, Sato K. Purification of gamma-glutamyltransferases from rat hepatomas and hyperplastic hepatic nodules, and comparison with the enzyme from rat kidney. Cancer Res 1979;39:4200-5.
72. Sawabu N, Nakagen M, Ozaki K, Wakabayashi T, Toya D, Hattori N et al. Clinical evaluation of specific gamma-GTP isoenzyme in patients with hepatocellular carcinoma. Cancer 1983;51:327-31.
73. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8.
74. Miller WJ, Baron RL, Dodd GD 3rd, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994;193:645-50.
75. Taourel PG, Pageaux GP, Coste V, Fahre JM, Pradel JA, Ramos J et al. Small hepatocellular carcinoma in patients undergoing liver transplantation: detection with CT after injection of iodized oil. Radiology 1995;197:377-80.
76. Gambarin M. Prospective study of screening for hepatocellular carcinoma in patients with cirrhosis. Am J Gastroenterol 2000;42:453-8.
77. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
78. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-8.
79. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533-42.
80. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30.
81. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7.
82. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8:S19-27.
83. Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol 1992;7:463-8.
84. Mima S, Sekiya C, Kanagawa H, Kohyama H, Gotoh K, Mizuo H et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994;9:361-5.